Abstract
The past 50 years have seen remarkable progress in improving the survival of children with cancer (Smith et al. 2010). Among the greatest of these successes are the outcomes for children with acute leukemia. To better understand the incidence and survival for children with all cancers, including leukemia, a comprehensive analysis was recently performed in the United States using the Surveillance, Epidemiology, and End Results 9 (SEER 9) Registry (Smith et al. 2010). This data showed an increased incidence rate for all cancers in children less than 20 years of age during the years 1975 through 2006 (Fig. 13.1). The incidence rates for lymphoid leukemia increased significantly during this time period, with an annual percentage change of 0.8%. Mortality rates for all childhood cancers combined declined by more than 50%, with an estimated 38,032 childhood cancer deaths averted in the United States during this 31-year time period (Fig. 13.2). Remarkably, there was a 64% reduction in mortality rates attributable to leukemia. However, despite these significant reductions in leukemia-specific mortality rates, death due to leukemia remained the leading cause of cancer death in children in both 1975 and in 2006.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arico M, Valsecchi MG et al (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342(14): 998–1006
Druker BJ, Sawyers CL et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344(14):1038–1042
Gaynon PS, Trigg ME et al (2000) Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia 14(12):2223–2233
Harvey RC, Mullighan CG et al (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leu-kemia. Blood 115(26): 5312–5321
Insitute of Medicine (2010) A national cancer clinical trials system for the 21st century: reinvigorating the NCI cooperative group program
Maloney KW, Shuster JJ et al (2000) Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994. Leukemia 14(12):2276–2285
Mauro MJ, O’Dwyer M et al (2002) STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20(1): 325–334
Mullighan CG, Miller CB et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110–114
Mullighan CG, Collins-Underwood JR et al (2009a) Re-arrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41(11):1243–1246
Mullighan CG, Su X et al (2009b) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360(5): 470–480
Mullighan CG, Zhang J et al (2009c) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106(23):9414–9418
Savage DG, Antman KH (2002) Imatinib mesylate – a new oral targeted therapy. N Engl J Med 346(9):683–693
Schultz KR, Bowman WP et al (2009) Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 27(31): 5175–5181
Smith MA, Seibel NL et al (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28(15):2625–2634
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Reaman, G.H., Smith, F.O. (2011). Future Challenges and Opportunities to Improve Outcomes for Children with Leukemia. In: Reaman, G., Smith, F. (eds) Childhood Leukemia. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13781-5_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-13781-5_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13780-8
Online ISBN: 978-3-642-13781-5
eBook Packages: MedicineMedicine (R0)